Bezlotoxumab (BEZ) for Prevention of Clostridium Difficile Infection (CDI) Recurrence (rCDI): Outcomes in Patients with Substantial Renal Impairment (SRI)

BACKGROUND: CDI in patients with SRI is harder to treat and is associated with higher recurrence. MODIFY I/II found that BEZ, a monoclonal antibody against C. difficile toxin B, is superior to placebo (PBO) at preventing rCDI in patients receiving standard of care antibiotics (SoC). This post hoc an...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Open Forum Infect Dis
Asıl Yazarlar: Golan, Yoav, DuPont, Herbert L, Aldomiro, Fernando, Jensen, Erin H, Hanson, Mary E, Dorr, Mary Beth
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2017
Konular:
Abstracts
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5630736/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofx163.962
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller